Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
explorer10: concizumab prophylaxis in children with haemophilia A or B
jRCT2031220097Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Open-label, single-arm trial of concizumab in hemophilia A and hemophilia B (HB), sponsored by Novo Nordisk. Primary endpoint: Number of treated spontaneous and traumatic bleeding episodes in inhibitor patients. Started Mar 2022; status: active, not recruiting.
02
Drugs
concizumab
03
Conditions
hemophilia Ahemophilia B (HB)
Beyond the preview
Go deeper on jRCT2031220097.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220097.